Clinical Decision Making in Advanced NSCLC without Actionable Mutations
Edgardo S. Santos, MD, FACP, discusses the current treatment landscape for patients with squamous cell carcinoma of the lung.
Julie Renee Brahmer, MD, discusses clinical trials investigating treatment options for patients with non–small cell lung cancer following progression after first-line immunotherapy.
Advertisement
Advertisement
Trending on OncLive
1
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
2
Long-Term Data Refine the Role of Immunotherapy Across Early-Stage NSCLC Settings
3
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
4
Dr Tarantino on the Evolution of TROP2-Directed ADCs in First-Line TNBC
5